Parallel Session: NAFLD and NASH: Therapeutics

Watch this live session to see some the top research in NAFLD and NASH. Content will only be aired on this date, at this time. Don't miss it!

• Novel, First-in-Class, Fatty Acic Synthase (FASN) Inhibitor, TVB-2640 Demonstrates Clinically Significant Reduction in Liver Fat by MRI-PDFF, and ALT in NASH: A Phase 2 Randomized Placebo-Controlled Trial (FASCINATE-1)
  Presenting Author Rohit Loomba
• Statin Use is Associated with Reduced Cancer-Related Mortality Among Patients with Non-Alcoholic Fatty Liver Disease: A National Prosepctive Cohort Study
• Hyperhomocysteinemia is a Marker and Mediator of NASH: Discovery of a Novel Vitamin Therapy (B12 and Folate) for NASH
  Presenting Madhulika Tripthai
• Evaluation of Obeticholic Acid Efficacy in Patients with NASH who were Monitored Using Noninvasive Tests: A Post Hoc Analyiss of the Regnerate Trial
  Presenting Author Naim Alkhouri
• Mitochondrial SAB (SH3BP5) is a Novel Target for Anisense Oligonucleotide (ASO) Treatment in Experiemental NASH and Fibrosis
  Presenting Author Sanda Win
• Final Analysis of a 24-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aldafermin (NGM282) In Patients with Nonalcoholic Steatohepatitis
  Presenting Author Stephen Harrison